JP2008500277A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500277A5
JP2008500277A5 JP2006552536A JP2006552536A JP2008500277A5 JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5 JP 2006552536 A JP2006552536 A JP 2006552536A JP 2006552536 A JP2006552536 A JP 2006552536A JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5
Authority
JP
Japan
Prior art keywords
cancer
days
human immunoglobulin
administration
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006552536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500277A (ja
JP5220315B2 (ja
Filing date
Publication date
Priority claimed from US10/778,915 external-priority patent/US20050180979A1/en
Application filed filed Critical
Publication of JP2008500277A publication Critical patent/JP2008500277A/ja
Publication of JP2008500277A5 publication Critical patent/JP2008500277A5/ja
Application granted granted Critical
Publication of JP5220315B2 publication Critical patent/JP5220315B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006552536A 2004-02-13 2005-02-09 抗EpCAM免疫グロブリン Expired - Fee Related JP5220315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 2004-02-13
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (3)

Publication Number Publication Date
JP2008500277A JP2008500277A (ja) 2008-01-10
JP2008500277A5 true JP2008500277A5 (cg-RX-API-DMAC7.html) 2008-04-03
JP5220315B2 JP5220315B2 (ja) 2013-06-26

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552536A Expired - Fee Related JP5220315B2 (ja) 2004-02-13 2005-02-09 抗EpCAM免疫グロブリン

Country Status (23)

Country Link
US (3) US20050180979A1 (cg-RX-API-DMAC7.html)
EP (2) EP1713830B1 (cg-RX-API-DMAC7.html)
JP (1) JP5220315B2 (cg-RX-API-DMAC7.html)
KR (1) KR101236224B1 (cg-RX-API-DMAC7.html)
CN (1) CN1976951B (cg-RX-API-DMAC7.html)
AT (1) ATE437186T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005215874B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507660A (cg-RX-API-DMAC7.html)
CA (1) CA2555694C (cg-RX-API-DMAC7.html)
DE (1) DE602005015544D1 (cg-RX-API-DMAC7.html)
DK (1) DK1713830T3 (cg-RX-API-DMAC7.html)
EA (1) EA011951B1 (cg-RX-API-DMAC7.html)
ES (1) ES2328159T3 (cg-RX-API-DMAC7.html)
IL (1) IL177069A (cg-RX-API-DMAC7.html)
MX (1) MXPA06008942A (cg-RX-API-DMAC7.html)
NO (1) NO339364B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ549125A (cg-RX-API-DMAC7.html)
PL (1) PL1713830T3 (cg-RX-API-DMAC7.html)
PT (1) PT1713830E (cg-RX-API-DMAC7.html)
SI (1) SI1713830T1 (cg-RX-API-DMAC7.html)
UA (1) UA87128C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005080428A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200606083B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351919A1 (en) 2003-01-24 2018-07-25 University of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2007090670A1 (en) 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
ATE512988T1 (de) 2007-04-04 2011-07-15 Sigma Tau Ind Farmaceuti Antikörper gegen epcam und anwendungen davon
EP2379747B1 (en) 2008-12-22 2013-07-03 University of Utah Research Foundation Monochrome multiplex quantitative pcr
CN102844443B (zh) * 2009-09-21 2014-08-06 保罗·沃尔菲什 用于甲状腺癌诊断和治疗的方法和组合物
JP6163502B2 (ja) * 2012-03-02 2017-07-12 アカデミア シニカAcademia Sinica 抗上皮細胞接着分子(EpCAM)抗体及びその使用方法
CN103409427B (zh) * 2012-09-24 2016-05-18 厦门大学 上皮细胞粘附分子的核酸适体EpCAM C及其制备方法
WO2014190138A2 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子(EpCAM)的单克隆抗体的制备、鉴定及应用
PL3553087T3 (pl) * 2014-01-08 2025-04-28 The Board Of Trustees Of The Leland Stanford Junior University Terapia celowana nowotworu złośliwego płuc
JP2018501799A (ja) 2014-12-30 2018-01-25 テロメア ダイアグノスティクス インコーポレイテッド マルチプレックス定量的pcr
DK3377103T4 (en) * 2015-11-19 2025-05-19 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN110035768A (zh) 2016-07-26 2019-07-19 泰莎治疗私人有限公司 嵌合抗原受体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
ATE200679T1 (de) * 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
CA2485691A1 (en) * 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Similar Documents

Publication Publication Date Title
JP2008500277A5 (cg-RX-API-DMAC7.html)
ES2981830T3 (es) Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
JP2007500236A5 (cg-RX-API-DMAC7.html)
JP2009506790A5 (cg-RX-API-DMAC7.html)
JP2006522830A5 (cg-RX-API-DMAC7.html)
JP2013533858A5 (cg-RX-API-DMAC7.html)
JP2020515578A5 (cg-RX-API-DMAC7.html)
JP2017160208A5 (cg-RX-API-DMAC7.html)
RU2020115713A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
JP2012518686A5 (cg-RX-API-DMAC7.html)
JP2009505676A5 (cg-RX-API-DMAC7.html)
JP2010535713A5 (cg-RX-API-DMAC7.html)
RU2013142004A (ru) Конъюгаты "антитело-лекарственное средство"
JP2011103891A5 (cg-RX-API-DMAC7.html)
JP2010531140A5 (cg-RX-API-DMAC7.html)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2015517523A5 (cg-RX-API-DMAC7.html)
JP2018512402A5 (cg-RX-API-DMAC7.html)
WO2021129616A1 (zh) 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
JP2008154589A5 (cg-RX-API-DMAC7.html)
JP2014510047A5 (cg-RX-API-DMAC7.html)
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
CN116712539A (zh) 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途